Leonard S. Schleifer, MD, PhD, founded the company in 1988 while serving as an Assistant Professor of Neurology at Weill Cornell Medical College. Leveraging a lifelong passion for science and an entrepreneurial spirit, he has served as a Director and its President and Chief Executive Officer since its inception and acted as Chairman of the Board from 1990 through 1994. Dr. Schleifer received his MD and PhD in Pharmacology from the University of Virginia, and he is a licensed physician certified in neurology by the American Board of Psychiatry and Neurology.
George D. Yancopoulos, MD, PhD, is Regeneron’s President and Chief Scientific Officer. He has led Regeneron alongside Len Schleifer, MD, PhD, since 1989. George has been driven by science his entire life. He began his education at the Bronx High School of Science, received his MD and PhD from Columbia University and went on to become the 11th most highly cited scientist in the world in the 1990s. In 2004, he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor and developer of Regeneron's six FDA-approved drugs, as well as its foundational technologies, including the Trap technology, VelociGene® and VelocImmune®.
The Regeneron Genetics Center (RGC) has built one of the world’s most comprehensive genetics databases, pairing the sequenced exomes and de-identified electronic health records of more than 300,000 people so far. Building upon our strengths in mouse genetics and genetics-driven drug discovery, this information will allow us to elucidate, on a large scale, genetic factors that cause or influence a range of human diseases. We believe that this knowledge can advance basic science around the world, provide clinically valuable insights to physicians and patients and ultimately make drug development faster and more precise.
Our team conducts gene sequencing projects, functional biology, disease modeling and the translation of genetics findings into Regeneron’s preclinical and clinical pipelines. We are using our unique database and state-of-the-art analysis capabilities to identify new drug targets and therapeutic indications, to validate our existing programs and to build better-informed clinical trials. Our explorations include Mendelian and family frameworks, large-scale population genetics (both common and rare variants) and gene-gene interactions.
Regeneron Pharmaceuticals CEO Leonard Schleifer said Monday the biotech firm is willing to lower the cost of its more than $14,000-per-year cholesterol drug for patients.
Regeneron (NASDAQ: REGN) is a leading science and technology company delivering life-transforming medicines for serious diseases.
Founded by physician-scientists 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including asthma, pain, cancer and infectious diseases.
In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human genetics sequencing efforts in the world and rapid response technologies being used for global good. – less